Fibrobiologics Inc. (FBLG)
Market Open
11 Sep, 16:00
NASDAQ (CM) NASDAQ (CM) Primary $
1. 69
-0.04
-2.3121%
$
3.58M Market Cap
- P/E Ratio
- Div Yield
32,006 Volume
- Eps
$ 1.73
Previous Close 
Want to track FBLG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a topically applied allogeneic cell therapy that uses donor fibroblasts, a type of specialized connective tissue cell, to accelerate wound healing.
Proactiveinvestors | 2 weeks ago
